Thinkcyte KK

TOKYO and REDWOOD CITY, Calif., Aug. 30, 2024 /PRNewswire/ -- ThinkCyte today announced the successful completion of its Series C funding round. Including the equity financing secured last November, the company raised an additional $15 million in the extension round, bringing the total to $32 million. The extension round was led by Japan Green Investment Corp. for Carbon Neutrality (JICN), KIRIN-GB Fund I L.P., and SMBC Venture Capital No. 7 Investment Limited Partnership. The company also secured a loan from Japan Finance Corporation. This latest round brings ThinkCyte's total funding to $91 million, reinforcing the company's commitment to expanding the global reach of its flagship product, VisionSort™. Since its launch in June 2023, VisionSort™ has been adopted by major biopharmaceutical companies and leading academic institutions worldwide. The new funding will drive production and manufacturing scale-up as well as help accelerate global commercial expansion. With this stable footing, ThinkCyte is poised to broaden the impact of its technologies, driving advancements in the life sciences and maintaining its leadership in innovative single-cell analysis and sorting solutions. About ThinkCyte ThinkCyte, founded in 2016 with offices in Tokyo, Japan and Redwood City, California is a biotechnology company that develops innovative scientific instruments based on integrated, multidisciplinary technologies to enable life science research, diagnostics, and therapeutic development. The company's flagship product, VisionSort, is the world's first AI-based, dual-mode fluorescence and morphometric cell sorting platform and it partners with major global biopharmaceutical companies and leading academic research institutes to further drive groundbreaking research. For more information, please visit . To learn more about research partnerships or other partnering opportunities with ThinkCyte, email [email protected]. SOURCE ThinkCyte Inc.

TOKYO, May 6, 2024 /PRNewswire/ -- ThinkCyte today announced that it will be presenting at three major international scientific conferences in the first week of May and the launch of its updated website. The company will have a presence at the American Society for Immunology (AAI) from May 3rd to 7th, the Association for Research in Vision and Ophthalmology (ARVO) from May 5th to 9th, and CYTO 2024 presented by the International Society for Advancement of Cytometry (ISAC) from May 4th to 8th. The events will showcase both internal research and development achievements as well as presentations from VisionSort customers on the application of the platform to advance research and therapeutic development efforts. Continue Reading The new ThinkCyte website was developed with the user experience in mind. "A year ago we launched VisionSort and had just been recognized for technology innovation at CYTO, the premiere international cytometry meeting," said Janette Phi, Chief Business Officer at ThinkCyte. "Since then we've had the privilege of working closely with our innovation-minded early adopter customers who have been instrumental in pushing the real-world applications of what this technology can do. The diversity of presentations this month and the new website reflects this growth and we look forward to another year of helping our customers advance cell-based R&D efforts in new and exciting ways." Developed with the user experience in mind, the updated site includes many new features including: Streamlined and user-friendly explanations of Ghost CytometryTM, the core technology inside VisionSort Easier access to VisionSort Resources including Application Notes, Publications, Posters, and Videos More info on VisionSort values for Cell Therapy R&D, Drug Discovery, & Disease Profiling A new Partnering Page for life science technology and Biopharma companies seeking to accelerate R&D of novel therapeutics with AI-based approaches. For more information about ThinkCyte's upcoming events, visit: About ThinkCyte ThinkCyte, founded in 2016 with offices in Tokyo, Japan and Redwood City, California is a biotechnology company that develops innovative scientific instruments based on integrated, multidisciplinary technologies to enable life science research, diagnostics, and therapeutic development. The company's flagship product, VisionSort, is the world's first AI-based, dual-mode fluorescence and morphometric cell sorting platform and it partners with major global biopharmaceutical companies and leading academic research institutes to further drive groundbreaking research. For more information, please visit . To learn more about VisionSort, the commercially available platform powered by Ghost Cytometry, visit or email [email protected]. To learn more about research partnerships or other partnering opportunities with ThinkCyte, visit or email [email protected]. SOURCE ThinkCyte Inc.

TOKYO, April 1, 2024 /PRNewswire/ -- ThinkCyte today announced the publication of a paper in the March issue of Cell Reports Methods on a new method for high-throughput drug discovery. Together with a joint research group including investigators at the University of Tokyo and the University of British Columbia, the team describes the development of an approach to identify new candidate drugs by CRISPR screening using Ghost Cytometry; its artificial intelligence (AI)-driven, label-free, morphology-based cell sorting technology. In the publication, 'Pooled CRISPR screening of high-content cellular phenotypes using ghost cytometry,' the team shows how VisionSort can be used to perform both label-free and fluorescence-based screening for a range of phenotypes relevant to drug discovery. Specifically, the approach enables CRISPR-based workflows, where individual genes in single cells are knocked out and screened for a desired biological response. The new approach allows for not only faster drug screening, but also opens the door to use a host of new morphology-driven phenotypes in drug discovery campaigns. The publication comes on the heels of an invited talk at the Society for Laboratory for Automation and Screening (SLAS) meeting in February where ThinkCyte presented how VisionSort was used to perform flow-based high content intracellular phenotypic screening using DNA barcoding technology. In December, the company was also profiled in a special edition of Cell Press highlighting the emerging uses of AI in drug discovery screening. "Our biopharma customers are looking to integrate new technologies to expand their phenotypic drug screening programs," said Janette Phi, Chief Business Officer at ThinkCyte. "With VisionSort, they can supplement their existing workflows with a fast and flexible new discovery tool that enables them to expand their screening capabilities and build more robust early drug pipelines." Open access to the publication can be found at (24)00062-6, About ThinkCyte ThinkCyte, founded in 2016 with offices in Tokyo, Japan and Redwood City, California is a biotechnology company that develops innovative scientific instruments based on integrated, multidisciplinary technologies to enable life science research, diagnostics, and therapeutic development. The company's flagship product, VisionSort, is the world's first AI-based, dual-mode fluorescence and morphometric cell sorting platform and it partners with major global biopharmaceutical companies and leading academic research institutes to further drive groundbreaking research. For more information, please visit . To learn more about research partnerships or other partnering opportunities with ThinkCyte, visit or email [email protected]. To learn more about VisionSort, the commercially available platform powered by Ghost Cytometry, visit . SOURCE ThinkCyte Inc.